Search

Displaying results 1371 - 1380 of 8412 in total
  1. Pathway

    Drospirenone Action Pathway

    smpdb.ca/view/SMP0126538
    Drug action

    Drospirenone is a synthetic progestin commonly found in popular oral contraceptives like Yaz, Angeliq, and Loryna. This drug is also indicated to control acne, menopause-associated symptoms, and premenstrual dysphoric disorder (PMDD) whe...

    Drugs: NADH · ATP · Progesterone · Testosterone · Estrone · Potassium cation +9 more
    Enzymes: Estradiol 17-beta-dehydrogenase 1
  2. Pathway

    Dienogest Action Pathway

    smpdb.ca/view/SMP0126541
    Drug action

    Dienogest is a semisynthetic progestogen derived from 19-nortestosterone and has antiandrogenic properties. This drug is used as a contraceptive or to treat endometriosis alone or combined with ethinylestradiol. Dienogest acts by binding...

    Drugs: NADH · ATP · Progesterone · Testosterone · Estrone · Potassium cation +9 more
    Enzymes: Estradiol 17-beta-dehydrogenase 1
  3. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis. … PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis.

  4. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. … Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of

    Products: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  5. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] It is an aglycosylated, fully human IgG1 monoclonal antibody that binds FcRn and blocks the receptor's recycling of immunoglobulin G (IgG), thereby lowering circulating IgG levels, including pathogenic

  6. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation

    Categories: P-glycoprotein substratesSynonyms: PD 0325901, PD-0325901
  7. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer.

  8. Drug

    Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10584
    ApprovedInvestigational

    Mixtures: TD VAX, TD-VAC 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN AMPUL
  9. Drug

    Iodine

    go.drugbank.com/drugs/DB05382
    ApprovedInvestigational

    Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds.

    Mixtures: VIL-Rx, Multi Cal Mag Liquid
  10. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]

    Categories: P-glycoprotein substrates